Cytokinetics (NASDAQ:CYTK) versus Briacell Therap (NASDAQ:BCTX) Head to Head Survey

Cytokinetics (NASDAQ:CYTK) and Briacell Therap (NASDAQ:BCTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Profitability

This table compares Cytokinetics and Briacell Therap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-3,201.47%	N/A	-43.75%
Briacell Therap	N/A	-479.97%	-182.26%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cytokinetics and Briacell Therap, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0	4	10	2	2.88
Briacell Therap	0	0	1	0	3.00

Cytokinetics presently has a consensus price target of $70.92, indicating a potential upside of 96.03%. Briacell Therap has a consensus price target of $32.00, indicating a potential upside of 3,885.06%. Given Briacell Therap’s stronger consensus rating and higher possible upside, analysts plainly believe Briacell Therap is more favorable than Cytokinetics.

Risk & Volatility

Cytokinetics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Insider and Institutional Ownership

15.4% of Briacell Therap shares are owned by institutional investors. 2.7% of Cytokinetics shares are owned by company insiders. Comparatively, 5.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cytokinetics and Briacell Therap”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$18.47 million	233.95	-$589.53 million	($5.29)	-6.84
Briacell Therap	N/A	N/A	-$4.79 million	($8.32)	-0.10

Briacell Therap has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Summary

Briacell Therap beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.